Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Optomed

3.70 EUR

0.00 %

5,610 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Investor consensus
Compare
0.00 %
-1.86 %
+1.51 %
-4.02 %
-10.30 %
-20.26 %
-12.32 %
-49.66 %
-19.21 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
79.38M EUR
Turnover
85.87K EUR
P/E (adj.) (25e)
-11.57
EV/EBIT (adj.) (25e)
-14.43
P/B (25e)
3.39
EV/S (25e)
4.42
Dividend yield-% (25e)
-
Coverage
Recommendation
Buy
Target price
4.80 EUR
Updated
17.12.2025
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
10.2
2026

Annual report '25

6.5
2026

Interim report Q1'26

8.5
2026

General meeting '26

Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Life Science Companies as Investments | Life Science Night Dec. 9, 202514:40
Video12/16/2025, 7:30 AM

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
Regulatory press release12/12/2025, 1:45 PM

Optomed Oyj: New shares subscribed for in Optomed Plc's directed share issue have been registered in the Finnish Trade Register

Optomed
Regulatory press release12/10/2025, 8:00 PM

Optomed Oyj: Inside information: Optomed Plc successfully completes directed share issue raising approximately EUR 6.0 million

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release11/7/2025, 7:48 AM

Redeye: Optomed Q3 (Review) - Solid growth with a positive devices segment development

Optomed
Regulatory press release11/6/2025, 7:00 AM

Optomed Oyj: Optomed Plc: Interim Report, January - September 2025

Optomed
Regulatory press release9/26/2025, 1:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Myllylä

Optomed
Regulatory press release9/26/2025, 1:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Piila

Optomed
Regulatory press release9/26/2025, 1:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Himberg

Optomed
Regulatory press release9/26/2025, 1:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Knuutti

Optomed
Regulatory press release9/23/2025, 6:00 AM

Optomed Oyj: Optomed's Board has resolved upon a new option plan

Optomed
Regulation of medical devices and diagnostics in Europe
Analyst Comment9/19/2025, 5:18 AM by
Antti Siltanen

Regulation of medical devices and diagnostics in Europe

The EU is the world's second largest market for medical devices after the United States. In this article, we will go through the basics of EU regulation from an investor's perspective.

BioretecAiforia TechnologiesNexstimBiohitOptomedRevenio GroupModulightDetection TechnologyNightingale HealthBittium
Regulatory press release9/9/2025, 6:30 AM

Optomed Oyj: Composition of Optomed's Nomination Board

Optomed
Classification of medical devices and regulatory processes in the United States
Analyst Comment9/8/2025, 9:56 AM by
Antti Siltanen

Classification of medical devices and regulatory processes in the United States

We continue our series of articles focusing on Life Science investing, the first four parts of which focused on drug development. Subsequent articles will cover medical devices.

BioretecNexstimOptomedRevenio GroupModulightBittiumDetection Technology
Press release8/8/2025, 1:30 PM

Redeye: Optomed Q2 - Soft Q2 sales raises the stakes for H2 recovery

Optomed
Regulatory press release8/8/2025, 12:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Calarco

Optomed
Regulatory press release8/8/2025, 12:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Mäkinen

Optomed
Regulatory press release8/8/2025, 12:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Wen

Optomed
Regulatory press release8/8/2025, 12:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Tauriainen

Optomed
Regulatory press release8/8/2025, 12:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Lee

Optomed
Regulatory press release8/8/2025, 12:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Salonen

Optomed
Forum discussions
Optomed board member Leana Wen has shared quite a nice link (seems to have received a good amount of coverage in the Washington Post :)) Especially point 6.+++++ https://www.washingtonpost.com/opinions/2026/01/06/health-care-glp-1s-vaccines-medical-innovations/?utm_source=chatgpt...
yesterday
by Mr. Stock
24
WJLS News Network | Beckley, W.Va. Beckley Medicaid Members Now Eligible for Free Diabetic Eye Exams and A1C... Spotted on a neighboring forum. Things seem to be progressing.
1/6/2026, 11:29 AM
by Tobias
17
There sure has been plenty of updates and it’s great for us owners to still be around. Hopefully ”Reiska” knows what he’s talking about and means this year: linkedin.com Optomed leadership team and Board of Directors have spent the past two days... Optomed leadership team and Board...
1/5/2026, 4:47 PM
by Mr. Stock
13
What is likely: Based on public descriptions, Retina Labs’ model looks more like a teleretina / human overread chain (capture → transmission → interpretation → report) than a 92229-type “AI interprets without physician overread” model. Retina Labs’ own materials contain references...
yesterday
by Mr. Stock
8
Shares are hitting the market at such a rate that it looks like a “final sell-off” is underway. Trading volume is quite brisk. I don’t think there’s any fear of it ending. 1.76M new shares just hit the market. My optimistic guess is that 500-700K of them will go up for sale immediately...
1/5/2026, 3:46 PM
by Bob Fleming
6
Topcon acquired Iris. It is therefore crystal clear that Iris’s website features, for instance, Signal (Optomed’s white label), but could those more knowledgeable explain WHY the Optomed Aurora is also in the photos on the page in question (isn’t this always with AEYE-ai)? IRIS Diabetic...
1/6/2026, 12:37 PM
by Mr. Stock
5
Earlier similar news: The news here seems to be that Medicaid screening, including home visits, is expanding, although they are only talking about cities of approx. 20,000 inhabitants at a time (Wheeling in the news linked by @sheikki, now Beckley as a new one). What’s positive here...
1/6/2026, 12:11 PM
by vesuri
5
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.